inactiv
vero
cellderiv
je
vaccin
china
japan
korea
region
live
attenu
hepat
vaccin
china
region
live
attenu
inactiv
pandem
season
influenza
vaccin
india
china
intern
oral
cholera
vaccin
vietnam
intern
previous
asian
manufactur
market
novel
vaccin
europ
unit
state
choos
distribut
innov
product
acellular
pertussi
live
attenu
varicella
vaccin
multin
compani
howev
increas
global
integr
take
place
multin
compani
acquir
asian
manufactur
eg
sanofiaventi
franc
acquir
shantha
biotechn
india
asian
compani
acquir
obtain
technolog
distribut
right
european
countri
eg
inactiv
polio
vaccin
serum
institut
india
ltd
acquir
bilthoven
biolog
netherland
astella
japan
acquir
recombin
influenza
hemagglutinin
protein
scienc
us
thai
govern
pharmaceut
organ
acquir
chimer
je
vaccin
sanofipasteur
franc
biolog
evan
india
acquir
je
vaccin
intercel
ag
austria
vaccin
codevelop
agre
entiti
develop
asian
countri
eg
genet
modifi
inactiv
hiv
vaccin
codevelop
sumagen
korea
univers
western
ontario
canada
mycobacteri
candid
tuberculosi
vaccin
codevelop
tianjin
cansino
biotechnolog
china
mcmaster
univers
canada
univers
influenza
vaccin
codevelop
xiamen
wantai
sanofipasteur
franc
novel
pneumococc
conjug
vaccin
codevelop
sk
chemic
korea
sanofipasteur
franc
role
asian
compani
develop
provid
neglect
improv
vaccin
region
develop
countri
gener
emerg
trend
illustr
joint
research
activ
agreement
nation
research
council
canada
chines
nation
biotec
group
cover
develop
h
influenza
type
hib
bival
conjug
vaccin
novel
mucos
adjuv
therapeut
vaccin
helicobact
pylori
infect
cell
cultur
manufactur
platform
viral
vector
vaccin
koreanmanufactur
biosimilar
gener
biolog
infliximab
licens
europ
step
toward
commerci
expans
asian
regionmanufactur
biolog
develop
countri
emerg
asia
base
new
multin
vaccin
compani
broad
develop
product
distribut
capabl
horizon
even
consolid
exist
compani
occur
elsewher
broad
incom
rang
within
countri
region
result
larg
popul
segment
suffici
mean
pay
vaccin
outofpocket
even
among
countri
otherwis
qualifi
econom
gavi
fund
eg
india
substanti
number
famili
avail
vaccin
cover
nation
epi
result
twotier
system
vaccin
parallel
publicpriv
dichotomi
healthcar
deliveri
gener
practition
serv
expatri
famili
gener
follow
current
us
european
australian
vaccin
recommend
modif
schedul
five
je
vaccin
develop
licens
asian
countri
wide
use
firstgener
inactiv
suckl
mous
brain
smb
deriv
vaccin
replac
rapidli
econom
disadvantag
countri
chines
develop
manufactur
live
attenu
inactiv
vaccin
strain
grown
primari
babi
hamster
kidney
phk
cell
higherincom
countri
vero
cellderiv
inactiv
vaccin
licens
unit
state
australia
canada
europ
well
sever
asian
countri
replic
chimer
yellow
feverj
viru
recombin
vaccin
manufactur
thailand
detail
provid
chapter
control
case
occasion
outbreak
far
eastern
subtyp
tickborn
enceph
viru
northeastern
china
changchun
biolog
institut
develop
formalininactiv
vaccin
deriv
human
isol
senzhang
strain
grown
phk
cell
cultur
relat
vaccin
prepar
central
european
strain
distribut
europ
describ
chapter
kyasanur
forest
diseas
viru
kfdv
highli
pathogen
member
famili
flavivirida
caus
zoonosi
kfd
transmit
bite
infect
tick
haemaphysali
spinigera
primarili
nymphal
stage
character
acut
febril
ill
sever
hemorrhag
manifest
first
describ
outbreak
center
karnataka
state
india
among
herder
villag
forest
exposur
consid
local
shimoga
district
area
state
howev
sinc
first
report
viru
found
area
india
includ
kutch
saurashtra
part
gujarat
state
andaman
island
west
bengal
estim
close
case
kfd
occur
india
everi
year
among
confirm
case
fatal
follow
outbreak
india
variou
vaccin
includ
formalin
inactiv
russian
spring
summer
enceph
viru
russian
springsumm
enceph
virusbas
mousebrain
vaccin
live
attenu
vaccin
serial
passag
tissu
cultur
tri
limit
success
final
formalin
inactiv
vaccin
kfd
viru
grown
chicken
embryo
fibroblast
test
larg
field
trial
among
inhabit
affect
villag
diseas
attack
rate
report
among
person
receiv
one
dose
among
recipi
two
dose
respect
compar
attack
rate
unvaccin
person
vaccin
efficaci
respect
vaccin
subsequ
commerci
produc
state
institut
anim
health
veterinari
biolog
hebbal
bangalor
central
kfd
prevent
effort
state
karnataka
annual
vaccin
done
sinc
shimoga
adjac
district
wherein
two
dose
vaccin
administ
individu
year
age
interv
month
period
booster
also
administ
month
howev
recent
observ
suggest
lower
field
effect
report
previous
especi
follow
singl
dose
overal
coverag
also
low
effect
among
individu
percept
valu
vaccin
risk
also
rang
wide
region
within
individu
countri
larg
enthusiast
accept
even
demand
addit
routin
vaccin
eg
je
vaccin
southern
southeast
asia
degre
skeptic
equal
deepli
wide
held
vaccin
hesit
europ
unit
state
within
last
year
japan
discontinu
routin
childhood
vaccin
program
combin
measlesmumpsrubella
influenza
je
withdrew
recommend
human
papillomaviru
hpv
vaccin
adolesc
owe
sever
instanc
incorrectli
think
coincident
advers
event
causal
relat
requir
subcutan
oppos
im
administr
vaccin
exemplifi
misattribut
advers
reaction
aris
case
extrapol
muscl
contractur
result
repeat
im
administr
antibiot
intramuscularli
administ
product
includ
vaccin
extrapol
unintend
consequ
imped
licensur
vaccin
newer
adjuv
mechan
action
requir
im
administr
global
spread
inform
concern
thimeros
content
childhood
vaccin
vaccineassoci
autism
activ
parent
concern
among
middleclass
famili
develop
countri
elsewher
parent
refus
routin
je
vaccin
korea
signific
declin
vaccin
coverag
occur
differ
context
seven
case
tempor
relat
case
anaphylact
shock
neurolog
diseas
includ
five
death
occur
case
could
exclud
causal
relat
administr
mousebrainderiv
vaccin
prompt
nation
debat
establish
vaccin
advers
event
report
scheme
nation
vaccin
injuri
compens
system
introduct
live
attenu
je
vaccin
deriv
nonneur
tissu
substrat
mosaic
describ
common
theme
highlight
repres
approach
uniqu
issu
hold
wider
interest
cover
elsewher
volum
review
specif
vaccin
region
concern
eg
pandem
influenza
je
vaccin
vaccin
topic
common
develop
countri
eg
initi
surround
inject
safeti
measl
neonat
tetanu
elimin
polio
erad
financ
mechan
concentr
instead
aspect
vaccin
develop
implement
organ
step
vaccin
develop
approv
product
recommend
deliveri
also
focu
childhood
vaccin
vaccin
select
countri
region
japan
acknowledg
innov
sever
vaccin
use
intern
includ
acellular
pertussi
live
attenu
varicella
vaccin
novel
vaccin
develop
japan
china
india
australia
vietnam
regionspecif
need
tabl
includ
vaccin
je
hantaan
htn
seoul
seo
virusrel
hfr
russian
springsumm
enceph
kfd
cholera
sever
acut
respiratori
syndrom
q
fever
addit
novel
attenu
strain
measl
mump
hepat
rotaviru
intranas
deliv
pandem
viru
deriv
product
distribut
princip
within
region
addit
novel
vaccin
hepat
e
potenti
broader
use
intern
indic
region
transit
provid
fillfinish
manufactur
capac
fullfledg
particip
biotechnolog
research
clinic
develop
text
continu
p
reason
low
vaccin
efficaci
coverag
rate
need
investig
appropri
vaccin
regimen
effect
control
requir
definit
newer
vaccin
approach
eg
chimer
viru
protein
subunit
vaccin
investig
potenti
replac
current
vaccin
elsewher
nearli
ident
strain
kfdv
isol
patient
suffer
acut
febril
ill
yunnan
provinc
china
seropreval
studi
indic
kfdv
nanjianyin
viru
relat
tickborn
flaviviru
may
present
variou
part
southwestern
china
viru
similar
kfdv
call
alkhurma
hemorrhag
fever
viru
isol
patient
febril
ill
saudi
arabia
overal
case
two
death
occur
sheep
camel
handler
expos
tick
ornithodoro
savignyi
diseas
confirm
widespread
countri
previous
consid
tickborn
diseas
diseas
place
kfd
viru
spread
like
dissemin
local
nevertheless
discoveri
antigen
relat
virus
elsewher
alkhurma
hemorrhag
fever
viru
suggest
potenti
widespread
use
kfd
vaccin
depend
public
health
need
hfr
widespread
rodentborn
bunyavir
zoonosi
asia
pantrop
infect
promin
capillari
hemorrhag
interstiti
nephriti
casefat
ratio
last
decad
caus
annual
case
republ
korea
case
china
although
diseas
well
known
part
russia
asia
sporad
occasion
epidem
diseas
among
farmer
soldier
other
expos
campestr
sylvat
habitat
larg
unknown
west
thousand
militari
case
death
occur
korean
war
diseas
describ
korean
hemorrhag
fever
etiolog
agent
elud
investig
novel
bunyaviru
htn
viru
isol
stripe
field
mous
apodemu
agrariu
prove
princip
viral
reservoir
area
asia
later
antigen
relat
seo
viru
isol
rattu
rattu
rattu
norvegicu
explain
occurr
sporad
hfr
case
outbreak
urban
area
subsequ
sin
nombr
relat
hantavirus
discov
western
hemispher
rare
encount
infect
rodent
lead
small
number
case
featur
promin
pulmonari
involv
multitud
hantavirus
describ
global
widespread
impact
hfr
china
led
public
health
author
pronounc
diseas
second
hepb
public
health
menac
begin
sever
chines
vaccin
manufactur
use
smb
primari
babi
gerbil
kidney
cell
gkc
phk
cell
produc
inactiv
monoval
vaccin
htn
seo
virus
gkc
vaccin
inactiv
two
formalin
subsequ
vero
cell
linederiv
vaccin
develop
vaccin
evalu
nine
chines
provinc
hyperendem
hfr
gkcderiv
vaccin
htn
viru
produc
seroconvers
put
protect
titer
neutral
antibodi
subject
three
primari
dose
day
proport
rise
booster
year
declin
year
year
similar
immunogen
result
report
phkderiv
vaccin
purifi
smb
vaccin
random
control
threearm
trial
gkc
vaccin
vaccin
subject
receiv
three
primari
dose
booster
year
hfr
case
observ
age
sex
residencematch
control
case
unvaccin
subject
similar
age
year
compar
none
vaccine
month
followup
protect
efficaci
lower
confid
limit
p
cumul
binomi
probabl
efficaci
three
primari
dose
alon
shown
year
administr
three
primari
dose
seri
booster
dose
zero
case
vaccin
nine
case
unvaccin
control
group
respect
among
case
control
unvaccin
group
caus
htn
viru
caus
seo
viru
four
viru
indetermin
serotyp
thu
monoval
gkcderiv
htn
viru
vaccin
protect
homolog
viru
also
crossprotect
seo
viru
vaccinerel
seriou
advers
event
report
trial
mild
local
systemat
reaction
report
vaccine
efficaci
phk
vaccin
purifi
smb
vaccin
similar
nonrandom
trial
one
hfr
case
found
recipi
phk
vaccin
compar
unvaccin
subject
reduct
purifi
smb
vaccin
rate
per
versu
per
vaccine
unvaccin
subject
respect
reduct
observ
reduct
maintain
year
followup
nonsever
reaction
found
phk
vaccin
recipi
smb
vaccin
recipi
bival
htn
seo
gkcand
phkderiv
vaccin
develop
improv
purif
procedur
gradient
densiti
ultracentrifug
chromatographi
immunogen
less
reactogen
purifi
bival
gkc
vaccin
induc
neutral
antibodi
seroconvers
htn
viru
seo
virus
volunt
respect
two
dose
interv
day
respect
booster
dose
month
mild
reaction
observ
local
reaction
system
reaction
vaccine
purifi
bival
phk
vaccin
induc
neutral
antibodi
seroconvers
htn
viru
seo
viru
subject
respect
two
dose
separ
day
respect
booster
dose
month
system
reaction
found
among
vaccine
mild
local
reaction
observ
two
purifi
bival
gkc
vaccin
test
protect
efficaci
nonrandom
trial
among
subject
year
age
person
receiv
two
primari
dose
interv
day
booster
dose
month
person
unvaccin
two
group
similar
age
distribut
year
followup
hfr
case
found
personyear
among
unvaccin
rate
per
compar
none
vaccin
personyear
reduct
sever
manufactur
adapt
process
primari
gerbil
hamster
cell
continu
vero
cell
purifi
bival
vero
cellderiv
vaccin
administ
two
dose
separ
day
induc
neutral
antibodi
htn
viru
seo
virus
adult
volunt
respect
mild
system
reaction
observ
mild
local
reaction
vaccin
recipi
immunogen
safeti
profil
vero
cellderiv
purifi
bival
vaccin
similar
children
older
adult
base
data
schedul
two
primari
dose
interv
day
plu
booster
month
recommend
purifi
bival
gkc
phk
verocellderiv
vaccin
postlicensur
retrospect
studi
conduct
measur
longterm
effect
gkc
vaccin
among
adult
year
age
villag
locat
hyperendem
area
shaanxi
provinc
hfr
incid
rate
compar
vaccin
unvaccin
adult
versu
respect
first
year
vaccin
versu
year
versu
year
versu
year
vaccin
effect
thu
estim
respect
four
studi
period
effect
underestim
year
onset
hfr
unknown
case
belong
unvaccin
group
includ
analysi
overal
hfr
attack
rate
vaccine
unvaccin
subject
reduct
longterm
studi
monoval
phkderiv
seo
viru
vaccin
also
conduct
among
adult
year
old
seo
viruspredomin
area
three
primari
dose
given
day
without
booster
seven
hfr
case
found
subject
vaccin
group
rate
per
case
found
control
rate
per
overal
reduct
ci
year
studi
vaccin
effect
estim
first
year
second
year
year
rate
reduct
year
approxim
smbderiv
htn
viru
vaccin
also
develop
republ
korea
avail
atrisk
individu
incid
hfr
china
korea
declin
last
year
introduct
vaccin
probabl
importantli
urban
rural
econom
develop
lead
improv
cement
hous
grain
harvest
storag
practic
result
reduc
exposur
rodent
reservoir
trend
evid
rapidli
develop
area
southeastern
china
like
continu
region
lead
diminut
diseas
incid
potenti
discontinu
routin
vaccin
endem
provinc
see
tabl
two
similar
live
attenu
hepat
vaccin
base
strain
measl
vaccin
base
shanghai
strain
licens
china
use
domest
export
nation
institut
hygien
epidemiolog
vietnam
develop
oral
bival
kill
wholecel
cholera
vaccin
produc
distribut
vabiotech
compani
vaccin
biolog
product
hanoi
anoth
oral
bival
vaccin
base
vabiotec
vaccin
improv
product
design
produc
india
shantha
sanofi
franc
vaccin
use
domest
also
export
similarli
live
rotaviru
vaccin
base
local
strain
develop
india
china
local
use
relat
enterovirus
emerg
major
season
epidem
asia
australia
lead
million
case
extens
social
disrupt
daycar
school
close
extent
impact
season
outbreak
stimul
vaccin
develop
china
taiwan
malaysia
singapor
japan
govern
priorit
support
countri
analog
mechan
facilit
pandem
influenza
vaccin
develop
escherichia
coliexpress
capsid
peptid
viruslik
particl
hepat
e
vaccin
approv
china
food
drug
administr
first
novel
recombin
vaccin
develop
licens
asia
potenti
use
africa
south
asia
possibl
even
develop
countri
immunocompromis
risk
group
could
envis
implicit
region
progress
toward
novel
vaccin
develop
matur
capac
conduct
clinic
trial
improv
toward
robust
regulatori
process
capac
includ
pharmacovigil
system
addit
multin
compani
increasingli
turn
countri
asia
conduct
clinic
trial
lower
cost
streamlin
regulatori
approv
clinic
trial
applic
intern
contract
research
organ
oper
mani
countri
grow
local
infrastructur
conduct
clinic
trial
complianc
intern
confer
harmon
technic
requir
registr
pharmaceut
human
use
good
clinic
practic
standard
improv
clinic
research
conduct
region
unlik
europ
asian
countri
unifi
central
regulatori
approv
process
region
public
health
presenc
latin
america
pan
american
health
organ
paho
lead
region
vaccin
program
also
provid
central
purchas
certain
qualifi
vaccin
howev
associ
southeast
asian
nation
asean
includ
bruneidarussalam
cambodia
indonesia
lao
pdr
malaysia
myanmar
philippin
singapor
thailand
vietnam
initi
effort
subregion
regulatori
harmon
scheme
reduc
differ
technic
requir
regulatori
procedur
pharmaceut
harmon
initi
auspic
pharmaceut
product
work
group
aim
remov
barrier
region
commerc
elimin
technic
barrier
trade
without
compromis
product
qualiti
efficaci
safeti
eventu
subregion
central
mutualrecognit
procedur
similar
european
union
could
envis
importantli
local
clinic
trial
requir
registr
abbrevi
pathway
specifi
asean
common
technic
dossier
vaccin
approv
licens
benchmark
regulatori
agenc
result
certif
pharmaceut
product
contrast
nation
regulatori
author
china
india
japan
korea
taiwan
requir
local
clinic
trial
registr
countri
data
local
popul
may
requir
registr
data
import
deliber
vaccin
inclus
nation
schedul
dengu
diseas
special
public
health
urgenc
region
global
debut
candid
vaccin
region
consid
individu
countri
vaccin
registr
ahead
approv
benchmark
agenc
provis
certif
pharmaceut
product
text
continu
p
variou
countri
region
effect
delay
registr
proven
vaccin
otherwis
could
prevent
signific
morbid
mortal
time
introduct
descript
individu
regulatori
requir
clinic
trial
applic
new
product
approv
beyond
scope
chapter
see
previou
edit
detail
introduct
govern
greater
role
vaccin
manufactur
region
elsewher
although
devolut
toward
privat
stateown
enterpris
ie
governmentown
corpor
occur
eg
commonwealth
serum
laboratori
australia
privat
six
major
govern
vaccin
institut
china
oper
stateown
enterpris
china
nation
biotech
group
see
tabl
although
grow
number
privat
manufactur
emerg
especi
china
india
countri
nation
local
govern
manufactur
continu
import
sourc
certain
vaccin
biolog
domest
need
eg
govern
pharmaceut
offic
thailand
research
institut
tropic
medicin
philippin
biofarma
indonesia
nation
institut
hygien
epidemiolog
vietnam
central
research
institut
local
govern
institut
india
facil
also
fill
distribut
bulk
vaccin
suppli
intern
manufactur
sever
privat
stateown
enterpris
manufactur
region
member
dcvmn
consortium
seek
identifi
develop
solut
common
challeng
face
manufactur
develop
countri
number
manufactur
includ
five
asiapacif
countri
oper
practic
procedur
prequalifi
produc
certain
vaccin
unicef
paho
gavi
purchas
eg
pentaval
dtp
combin
oral
polio
vaccin
inactiv
polio
vaccin
hepb
rabi
influenza
oral
cholera
measlescontain
vaccin
allow
export
vaccin
countri
region
reliabl
suppli
inexpens
diphtheria
tetanu
toxoid
combin
wholecel
pertussi
dtwp
hibhepb
combin
vaccin
made
possibl
larg
indian
korean
manufactur
facilit
introduct
hib
antigen
schedul
econom
disadvantag
countri
otherwis
would
adopt
monoval
vaccin
similarli
provis
measl
measl
contain
vaccin
indian
manufactur
key
elimin
diseas
latin
america
current
state
polio
elimin
could
achiev
without
suppli
asian
region
manufactur
provis
oral
cholera
vaccin
outbreak
control
haiti
pakistan
countri
import
exampl
increas
abil
global
depend
manufactur
prequalif
requir
manufactur
plant
must
satisfi
good
manufactur
practic
inspect
addit
nation
notif
advers
event
follow
immun
captur
analyz
satisfactorili
last
requir
princip
impedi
prequalif
product
countri
prequalif
aid
blueprint
vaccin
safetyrel
guidelin
facilit
improv
vaccinerel
pharmacovigil
region
china
stateown
china
nation
biotec
group
domin
supplier
vaccin
countri
provid
dose
use
public
program
taken
initi
collabor
among
nongovernment
organ
dengu
vaccin
initi
world
health
organ
develop
countri
vaccin
regulatori
network
dcvrn
dcvrn
activ
work
toward
harmon
procedur
affili
countri
includ
china
india
indonesia
bring
regul
prequalif
umbrella
facilit
approv
suppli
product
gavi
unit
nation
children
fund
unicef
requir
nation
regulatori
author
clinic
data
local
popul
base
concern
racial
ethnic
environment
differ
could
affect
respons
local
popul
immunolog
risk
advers
event
genet
base
differ
drug
pharmacokinet
pharmacodynam
well
diseas
risk
increasingli
recogn
includ
immun
respons
vaccin
studi
antibodi
respons
pneumococc
conjug
vaccin
asia
exampl
found
higher
prevaccin
postvaccin
antibodi
titer
among
philippin
taiwanes
infant
compar
european
histor
control
subject
korea
consider
higher
proport
subject
seroposit
meningococc
serogroup
polysaccharid
baselin
unit
state
basi
differ
may
earlier
exposur
life
cognat
crossreact
antigen
eg
region
differ
host
microbiom
genet
restrict
respons
observ
hepb
measl
vaccinia
rubella
hib
antigen
case
oral
rotaviru
vaccin
genet
determin
viral
attach
receptor
bind
molecul
describ
perspect
advers
event
follow
immun
exampl
narcolepsi
occur
recipi
adjuv
pandem
vaccin
illustr
role
genet
background
cofactor
risk
mani
exampl
regulatori
system
process
region
effect
markedli
slow
effect
block
introduct
novel
vaccin
develop
extern
china
introduct
intern
regist
otherwis
wide
use
product
nevertheless
necessit
recapitul
entir
clinic
develop
program
china
includ
phase
studi
despit
abund
previous
scrutin
evid
requir
introduc
delay
decad
registr
intern
develop
oppos
domest
develop
vaccin
specif
nation
pharmacopeia
deviat
establish
compendia
exampl
exclus
wellaccept
excipi
method
also
serious
imped
prevent
registr
foreign
product
impos
revis
pharmacopeia
led
withdraw
previous
regist
product
clinic
trial
process
also
hinder
local
introduct
establish
novel
product
eg
indian
suprem
court
order
suspens
ongo
clinic
trial
reexamin
previous
approv
trial
follow
wholesal
revis
clinic
trial
guidelin
lead
temporari
cessat
industrysponsor
clinic
trial
activ
potenti
inclus
video
record
inform
consent
process
newer
insur
requir
propos
unclear
amend
drug
cosmet
act
could
impos
crimin
penalti
trial
investig
poorli
defin
violat
may
limit
trial
activ
china
indonesia
place
sever
restrict
export
clinic
sampl
studi
subject
therebi
requir
valid
laboratori
procedur
establish
local
ad
barrier
led
delay
avoid
clinic
studi
countri
whether
result
inexperi
dearth
train
personnel
trade
protect
reason
administr
mechan
countri
region
public
health
author
draw
extern
advisor
help
formul
nation
vaccin
recommend
nation
immun
technic
advisori
group
nitag
result
part
activ
support
independ
immun
vaccin
advisori
committe
initi
agenc
de
advisori
committe
immun
practic
acip
taiwan
korea
expert
committe
immun
singapor
chines
expert
committe
epi
hong
kong
scientif
committe
vaccin
prevent
diseas
immun
committe
indonesian
pediatr
societi
nation
technic
advisori
group
immun
india
australian
technic
advisori
group
immun
exampl
medic
advisori
group
china
vaccin
recommend
made
nation
center
diseas
control
base
recommend
chines
expert
committe
epi
ministri
health
famili
welfar
howev
provinci
local
center
diseas
control
may
issu
independ
recommend
specif
vaccin
modifi
nation
recommend
routin
vaccin
see
tabl
issu
consid
asian
nitag
formul
vaccin
recommend
parallel
nitag
focus
medic
need
vaccin
safeti
efficaci
nation
resourc
well
implement
issu
includ
suppli
coldchain
fit
within
nation
schedul
vaccin
present
etc
health
econom
analys
consid
deliber
committe
provid
independ
bodi
eg
health
intervent
technolog
assess
program
thailand
although
gener
use
health
technolog
assess
region
lag
behind
unit
state
unit
kingdom
case
industri
sponsor
provid
analys
nitag
justif
includ
new
vaccin
nation
program
play
role
introduc
costtobenefit
analys
recommend
process
indonesia
malaysia
halal
statu
vaccin
import
factor
public
accept
product
also
consider
vaccin
recommend
process
although
movement
remov
consider
debat
certain
asian
countri
well
latin
america
approv
process
includ
new
vaccin
nation
program
use
leverag
multin
compani
foster
local
manufactur
expertis
brazil
technolog
transfer
vaccin
product
process
requir
turn
vaccin
inclus
nation
schedul
indonesia
epi
vaccin
local
produc
biofarma
new
vaccin
introduc
nation
schedul
unless
produc
local
technolog
transfer
element
manufactur
process
also
factor
introduct
new
vaccin
thailand
malaysia
requir
may
test
costli
vaccin
manufactur
complex
technolog
introduc
region
recommend
process
japan
illustr
even
registr
organiz
administr
process
result
lengthi
interv
new
vaccin
introduc
nation
schedul
although
sinc
japan
recov
vaccin
gap
selfacknowledg
interv
antigen
hib
pneumococc
conjug
rotaviru
hpv
inactiv
polio
variou
combin
vaccin
introduc
japan
despit
widespread
use
develop
countriesadopt
new
vaccin
nation
immun
program
registr
still
lag
sever
year
number
sequenti
approv
lengthen
process
immun
polici
vaccin
committe
provid
initi
recommend
whether
newli
regist
vaccin
privat
group
compris
manufactur
site
produc
product
includ
first
prequalifi
vaccin
produc
china
je
vaccin
privat
compani
compet
princip
provid
vaccin
outofpocket
sale
local
center
diseas
control
prevent
hospit
within
asean
commun
compris
princip
lowand
middleincom
countri
region
vaccin
secur
focu
discuss
reflect
establish
aseannetwork
drug
diagnost
vaccin
innov
focus
broad
agenda
health
technolog
develop
collabor
vaccin
manufactur
plan
region
vaccin
purchasingsimilar
paho
revolv
fund
similarli
eightnat
south
asian
associ
region
cooper
includ
biotechnolog
agenda
cooper
research
goal
achiev
selfreli
vaccin
suppli
also
articul
korea
horizonset
grow
extent
multin
compani
acquir
partner
local
compani
region
result
manufactur
standard
regul
improv
toward
meet
intern
specif
tabl
list
region
princip
vaccin
manufactur
licens
product
list
intend
comprehens
sometim
rapid
emerg
disappear
pharmaceut
vaccin
compani
china
elsewher
difficult
track
vaccin
manufactur
elsewher
refil
distribut
local
manufactur
list
countri
region
divid
broadli
countri
singl
nation
schedul
countri
basic
schedul
free
epi
vaccin
supplement
recommend
profession
organ
nation
pediatr
societi
addit
antigen
paid
outofpocket
countri
first
group
includ
one
hand
mainli
develop
countri
offer
basic
epi
schedul
countri
like
australia
new
zealand
taiwan
provid
univers
vaccin
program
includ
array
antigen
combin
vaccin
parallel
european
us
schedul
continu
introduct
new
frequent
expens
vaccin
ongo
tension
vaccin
recommend
fund
entiti
must
weigh
rel
valu
innov
prevent
therapeut
health
expenditur
even
lowmiddleincom
countri
region
total
per
capita
expenditur
healthcar
may
less
cost
full
cours
novel
vaccin
hand
nation
schedul
region
comprehens
includ
hpv
vaccin
australia
influenza
varicella
vaccin
eg
korea
taiwan
time
hib
vaccin
still
recommend
jurisdict
high
per
capita
incom
hong
kong
singapor
degre
seemingli
paradox
recommend
rel
highincom
countri
region
reflect
differ
social
expect
person
respons
healthcar
purchas
see
subsequ
text
shown
tabl
nation
schedul
provid
option
recommend
antigen
mani
countri
govern
tender
choos
specif
manufactur
product
specif
combin
recommend
nation
schedul
addit
antigen
provincialspecif
recommend
address
region
differ
risk
eg
routin
group
ac
meningococc
vaccin
china
je
vaccin
sarawak
malaysia
torr
strait
australia
rabi
vaccin
preexposur
area
philippin
classifi
either
routin
voluntari
base
avail
data
technic
recommend
consid
tuberculosi
infecti
diseas
control
divis
make
administr
decis
vaccin
inclus
nation
schedul
howev
decis
requir
addit
legisl
approv
whether
diseas
categori
b
qualifi
full
partial
vaccin
fund
circa
respect
recommend
process
even
lengthier
appear
suggest
immun
polici
vaccin
committe
conven
delib
vaccin
work
group
product
regist
unlik
parallel
activ
us
acip
food
drug
administr
committe
assembl
dossier
fact
sheet
establish
epidemiolog
diseas
local
burden
insuffici
data
avail
de
novo
studi
might
requir
establish
need
overal
interv
vaccin
approv
issuanc
recommend
typic
year
asian
countri
similar
even
lengthier
interv
vaccin
registr
full
epi
implement
thailand
exampl
preliminari
nitag
recommend
new
vaccin
implement
pilot
program
establish
effect
collect
addit
safeti
experi
program
may
gradual
extend
local
period
long
decad
antigen
provid
nation
diseas
region
differ
diseas
burden
highrisk
provinc
may
cover
first
eg
je
vaccin
initi
introduc
thailand
eight
highincid
provinc
progress
provinc
local
product
establish
expand
new
often
costli
vaccin
phase
introduct
provid
mechan
accommod
full
epi
coverag
cost
time
interim
local
govern
wealthier
provinc
municip
issu
recommend
vaccin
reimburs
eg
shanghai
provid
pneumococc
polysaccharid
vaccin
free
cost
older
adult
bangkok
establish
schoolbas
hpv
vaccin
program
neither
vaccin
includ
respect
nation
schedul
innov
financ
mechan
play
import
role
introduct
vaccin
lowincom
countri
extens
graduat
gavi
enabl
rapid
adopt
new
vaccin
countri
time
tier
price
negoti
sponsor
local
govern
entiti
aid
middl
incom
countri
acceler
vaccin
adopt
exemplifi
introduct
pcv
rotaviru
vaccin
interv
vaccin
registr
inclus
nation
schedul
avail
without
cost
outofpocket
sale
still
may
result
consider
uptak
rotaviru
vaccin
still
consid
voluntari
vaccin
japan
coverag
among
infant
estim
approxim
korea
although
almost
pediatr
vaccin
selfpaid
parent
vaccin
coverag
antigen
hib
pneumococc
conjug
vaccin
rapidli
reach
coverag
rate
approxim
herd
effect
led
disappear
respect
diseas
quickli
countri
although
japan
voluntari
vaccin
recommend
eman
govern
committe
countri
academ
societi
play
princip
role
recommend
vaccin
includ
epi
schedul
malaysian
pediatr
associ
pediatr
societi
thailand
philippin
foundat
vaccin
advis
respect
ministri
nitag
formul
nation
recommend
also
promulg
recommend
schedul
administr
approv
epicov
antigen
emul
larg
part
entir
us
australian
european
schedul
vaccin
deliv
vari
proport
public
privat
channel
depend
mainli
local
incom
level
access
privat
practition
gener
vaccin
nation
schedul
avail
cost
primari
health
center
equival
eg
puskesma
indonesia
polyclin
govern
hospit
clinic
singapor
malaysia
thailand
villag
counti
level
center
diseas
control
china
villag
commun
vietnam
public
health
center
clinic
india
japan
gener
practition
offic
japan
australia
vaccin
gener
avail
free
public
clinic
even
affluent
countri
famili
may
obtain
govern
clinic
hospit
eg
singapor
famili
obtain
vaccin
govern
system
polyclin
hospit
howev
avoid
long
wait
time
rotat
staff
public
clinic
mani
famili
opt
obtain
otherwis
free
vaccin
privat
pay
outofpocket
pediatr
gener
practition
privat
clinic
addit
newer
vaccin
may
delay
introduct
nation
reimburs
scheme
common
parent
pay
voluntarili
vaccin
see
earlier
might
expect
distribut
incom
proport
children
vaccin
govern
primari
health
center
higher
rural
area
overal
approxim
children
thailand
malaysia
vaccin
public
channel
china
vaccin
control
center
diseas
control
prevent
therefor
nearli
chines
children
receiv
free
epi
vaccin
well
payabl
option
vaccin
eg
hib
pneumococc
conjug
vaccin
varicella
rotaviru
other
public
clinic
fig
summar
coverag
epi
vaccin
select
countri
supplementari
immun
activ
play
critic
role
elimin
polio
southeast
asian
region
achiev
ongo
effort
elimin
measl
congenit
rubella
syndrom
routin
supplementari
immun
activ
tetanu
vaccin
elimin
matern
neonat
tetanu
four
countri
region
cambodia
indonesia
papua
new
guinea
pakistan
econom
growth
develop
asia
secular
trend
popul
structur
evolut
healthcar
system
forc
inevit
chang
variou
aspect
immun
region
asyet
unforese
way
popul
asia
region
age
shift
toward
structur
larger
proport
adult
elderli
person
birth
cohort
asia
decreas
slightli
million
popul
children
year
old
hold
nearli
constant
number
proport
adult
year
increas
dramat
number
peopl
older
year
age
nearli
doubl
million
demograph
crossov
point
adult
year
age
children
younger
year
age
reach
europ
occur
within
anoth
gener
asia
fig
except
almost
univers
epi
program
tetanu
toxoid
vaccin
pregnant
women
adult
vaccin
view
mainli
context
travel
group
meningococc
vaccin
hajj
tropic
asia
influenza
vaccin
allianc
vaccin
immunizationelig
countri
shade
similar
coverag
rate
basic
vaccin
countri
higher
level
econom
develop
illustr
success
expand
programm
immun
hepat
interestingli
princip
risk
cohort
young
adult
rais
era
econom
develop
improv
sanit
therefor
lack
natur
immun
born
routin
childhood
vaccin
implement
catchup
program
address
epidemiolog
shift
recogn
adult
vaccin
recommend
countri
see
tabl
china
adult
measl
vaccin
discuss
case
occur
annual
recent
year
equal
proport
adult
older
year
infant
receiv
first
vaccin
dose
grow
awar
adult
vaccin
reflect
increas
number
countri
adult
vaccin
recommend
see
tabl
two
popul
trend
influenc
demand
vaccin
channel
deliveri
urban
incom
dispar
urbandwel
popul
asia
project
increas
almost
billion
person
billion
billion
rural
popul
declin
slightli
urban
crowd
like
affect
transmiss
pattern
certain
persontoperson
transmit
diseas
even
infect
acquir
environment
sourc
dengu
exampl
transmit
mosquito
vector
preval
urban
environ
alreadi
great
need
dengu
vaccin
almost
certainli
increas
growth
urban
center
grow
size
number
larg
citi
may
increas
transmiss
certain
infect
deliveri
vaccin
healthcar
gener
better
organ
citi
rural
area
specif
intervent
need
ensur
exist
dispar
access
healthcar
urban
rural
dweller
widen
associ
urban
increas
incom
gap
mani
countri
health
arena
translat
twotier
system
healthcar
includ
prevent
medicin
vaccin
regard
mani
public
good
provid
govern
servic
mention
access
increas
number
new
vaccin
like
stratifi
incom
level
abil
pay
govern
must
choos
among
increasingli
costli
vaccin
health
intervent
shown
tabl
pediatr
societi
number
countri
promulg
recommend
emul
us
acip
schedul
aim
practition
serv
privatepay
famili
may
diverg
increasingli
nation
epi
schedul
benefit
major
children
countri
public
govern
respond
increas
dispar
perceiv
basic
medic
servic
remain
seen
come
year
novel
vaccin
like
develop
asia
licens
first
asia
region
develop
world
intern
market
govern
asean
express
increas
interest
provid
nation
region
vaccin
secur
collabor
industri
sponsor
nongovernment
organ
govern
public
privat
partnership
new
product
develop
highlight
success
introduct
vaccin
drug
sever
neglect
diseas
dcvmn
view
respons
exampl
japan
intern
cooper
agenc
kitasato
daiichi
sankyo
provid
technic
assist
establish
domest
measlesrubella
vaccin
product
vietnam
public
corpor
center
research
product
vaccin
biolog
polyvac
time
entri
nongovernment
organ
actual
sponsor
novel
vaccin
develop
certain
target
diseas
introduc
competit
dcvmn
manufactur
multin
compani
might
also
consid
similar
develop
program
asian
academ
institut
compani
possess
element
crossov
point
popul
adult
older
year
age
exceed
popul
children
younger
year
age
cross
europ
around
crossov
project
occur
asia
around
within
gener
travel
temper
locat
howev
sever
acut
respiratori
syndrom
pandem
outbreak
region
threat
influenza
focus
attent
routin
season
influenza
vaccin
first
time
mani
countri
begin
elderli
popul
role
children
influenza
transmiss
recogn
rediscov
japan
result
high
pediatr
vaccin
coverag
develop
countri
region
je
becom
almost
exclus
diseas
adult
older
year
age
reflect
intrins
biolog
suscept
older
adult
neurotrop
flavivirus
suggest
scientif
technic
expertis
need
develop
vaccin
current
emerg
need
seemingli
establish
global
stage
contribut
develop
region
institut
respond
rapidli
threat
middl
east
respiratori
syndrom
viru
ebola
viru
candid
vaccin
develop
even
transmiss
geograph
remot
particip
region
institut
global
respons
futur
like
trend
toward
increas
local
develop
manufactur
region
accompani
need
strengthen
respect
regulatori
agenc
recogn
local
nation
regulatori
author
revis
harmon
guidelin
procedur
intern
standard
enforc
procedur
consist
predict
manner
improv
time
region
introduct
vaccin
develop
intern
import
complianc
intern
standard
requir
region
manufactur
hope
licens
local
develop
vaccin
broadli
indian
chines
manufactur
current
export
limit
number
vaccin
mainli
region
african
latin
american
countri
horizon
undoubtedli
expand
sixcompon
framework
product
develop
capabilitymanufactur
nation
intern
distribut
system
privat
public
r
capabl
intellectu
properti
system
drug
vaccin
regulationregion
manufactur
differ
stage
matur
ascend
advanc
countri
produc
complex
biolog
well
high
technolog
product
korea
follow
path
might
emul
other
region
highlight
arriv
stage
nation
system
innov
scienc
technolog
link
govern
univers
industri
strong
regulatori
system
observ
intellectu
properti
right
includ
adher
traderel
aspect
intellectu
properti
right
trip
agreement
specif
area
regulatori
control
need
particular
attent
strengthen
nation
control
laboratori
mani
countri
lack
laboratori
capac
test
sampl
lot
releas
manufactur
test
technolog
chang
rapidli
keep
new
procedur
purchas
need
equip
ongo
challeng
continu
support
also
need
produc
work
quantiti
refer
standard
valid
new
assay
staff
train
profici
test
resourc
unavail
mani
countri
establish
maintain
fulli
function
nation
control
laboratori
region
network
propos
approach
share
expertis
divid
workload
time
standard
method
criteria
field
surveil
advers
event
follow
immun
anoth
area
requir
strengthen
investig
adjuv
pandem
prepandem
vaccin
administ
korea
taiwan
respect
illustr
interest
epidemiolog
capac
local
investig
also
limit
exist
system
databas
japan
establish
databas
clinic
encount
link
immun
record
could
use
futur
advers
event
surveil
system
regulatori
oversight
clinic
trial
human
subject
protect
area
grow
pressur
improv
multin
compani
increas
number
clinic
trial
asian
countri
reduc
cost
obtain
local
registr
product
activ
serv
import
role
strengthen
local
complianc
good
clinic
practic
mani
group
conduct
trial
region
limit
experi
precept
procedur
countri
region
interest
establish
enforc
clear
guidelin
host
increas
number
trial
also
manufactur
futur
sponsor
new
product
account
intern
uphold
recogn
standard
